August 3, 2017 07:53 AM EDT
R&D

Shire plots an AD­HD pub­lic spin­off as CEO Orn­skov com­pletes a top-to-bot­tom over­haul

John Carroll

Editor & Founder

Hard on the heels of win­ning an ap­proval for its long-last­ing ver­sion of Adder­all for AD­HD, Shire says it’s now con­sid­er­ing spin­ning off its block­buster …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times